PATENT CLAIM ANALYSIS

Application Number: 16020395
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "001900"]

Abstract:
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.

Claim (Index 5):
The method of  claim 1 , wherein the amino acid sequence has Q, N, L, V, I, or A at at least one position 3, 14, or 23.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 94.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14774682', '14216749', '12519116', '12999966', '11014187']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8135853822521222
- 35 USC 102 Novelty (BERT): 0.6732810550438117
- Combined Prediction Score: 0.7995549495312911
- Mean Citation Score: 534.392214
- Max Citation Score: 703.3606
- Similarity Product: 629.8598814776421

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test